GENENTECH, INC for GENENTECH INC
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Intellectual Property and Process Patent Issues; HR 1908, Patent Reform Act (all provisions); S.23 - Patent Reform Act; General Patent Reform Issues; Specfic issues lobbied (bill numbers): Patent reform legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Director |
| ELI KOGAN | Assoc.Director |
| EVAN MORRIS | VP Government Affairs |
| KATHERINE RAAB | Director |
Food Industry (safety, labeling, etc.) FOO
Monitor and report on food safety and supply chain issues;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assoc. Director |
| EVAN MORRIS | VP Director |
Trade (domestic/foreign) TRD
Montior issues related to export rules and regulations, international patent issues, WTO matters, the Trans-Pacific, Partnership and other international issues impacting biotech and pharmaceuticals
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assoc. Director |
| DARIN GARDNER | Director |
| EVAN MORRIS | VP Government Affairs |
| KATHERINE RAAB | Director |
Health Issues HCR
HCR: Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and FDA approval of follow on biologics. Public law111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid payment for biotherapeutics, the 340B program, and Medicared drug benefit.; Prescription Drug User Fee Act (PDUFA); Avastin - use in breast cancer treatment; Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis. Implementation of the Affordable Care Act of 2010; Advocate for approval of Avastin for late stage breast cancer treatment; HR 1/1473 - health care funding: FY12 Labor HHS Appropriations legislation Congress and Federal Agencies: U.S. House of Representatives; US Sentate; Implementation of HR 1; Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDFUA, stimulus. Issues relatiing to comparative effectiveness and CMS coverage of FDA approved therapies. Issues related to the PPS rule involving stroke guidelines. Implementation of the follow-on biolotics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act"; FDA approval and enforcement issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assoc. Director of Government Affairs |
| DARIN GARDNER | Director of Government Affairs |
| ELI KOGAN | Assoc. Director of Government Affairs |
| EVAN MORRIS | Vice President of Government Affairs |
Medicare/Medicaid MMM
Medicare coverage and payment of Part B drugs and biologicals; Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics. Participated in discussions with House and Senate staff on Medicare coverage/payment issues related to cance biotherapeutics, including Avastin and Lucentis.; Implementationof H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA, stimulus. Issues relating to comparative effectiveness and CMS coverage of FDA approved therapies. Issues related to the PPS rule involving stroke guidelines; Public Law 111-148, the Patient Protectiona and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics. Participated in discussions with House and Senate staff on Medicare coverage/payment issues related to cancer biotherapeutics, including Avastin and Lucentis; Monitor implentation of Medicine pharmaceutical coverage and reimbursement provisions of the Affordable Care Act; medicare issues; Implementation of P.L. 108-173, matters related to Medicare and Medicare Coverage and Reimbursement (Medicare Prescription Drug Act of 2003); Issues relating to prescription Drud User Fee Act: issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin, Issues related to coverage of Lucentis and Avastin.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Assoc. Director |
| DARIN GARDNER | Director |
| EVAN MORRIS | VP Government Affairs |
Budget/Appropriations BUD
FY11, FY12 Labor, HHS and Education Appropriation related to preparedness for pandemic influenza, HIV/AIDS programs, hepatitis screening, care and treatment, and access to breast cancer treatment. Implementation of H.R. 2346, S. 1054 FY09 Supplemental Appropriations related to preparedness for pandemic influenza.; issues related to pandemic preparedness and macular degeneration. FY11 appropriations process - including HR 1 and various Continuing Resolutions
| Lobbyist | Covered position, as disclosed |
|---|---|
| EVAN MORRIS | VP Government Affairs |
| KATHERINE RAAB | Director Government Affairs |
Pharmacy PHA
Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program, structure of the Medicar prescription drug benefit. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid reimbursement, fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription. drug benefit. General issue and congressional oversight related to FDA approval and CMS coverage decisions regarding. Avastin and Lucentis.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Director |
| EVAN MORRIS | VP Government Affairs |
| KATHERINE RAAB | Director |
Medical/Disease Research/Clinical Labs MED
Public Law 111-148, the Patient Protection and Affordable Care Act of 2009 - Implementation issues related to the authorization for comparatice effective research and the Patient-Centered Outcomes Research Institute.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Director |
| EVAN MORRIS | VP Government Affairs |
| KATHERINE RAAB | Director |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.